Navigation Links
ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
Date:10/30/2008

- Dr. Jeffrey A. Niezgoda and Dr. Peter J. Sordi provide updates on a wide

range of patient treatment experiences with Altrazeal(TM) -

- John St. John, Ph.D. gives perspectives on design and features of

Altrazeal(TM) -

LAS VEGAS, Oct. 30 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) -- Clinical updates and new case studies on the application of Altrazeal(TM) - Transforming Powder Dressing were presented yesterday at a special session of this year's annual Clinical Symposium on Advances in Skin & Wound Care. The session was hosted by ULURU Inc.

Dr. Jeffrey A. Niezgoda, M.D., FACHM, FAPWCA, director of the Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, Aurora Health Care, presented in-depth clinical updates on patients treated with Altrazeal(TM). Cases included venous ulcers, a diabetic foot ulcer, and a chronic wound associated with a mastectomy and radiation therapy. In many cases, patients treated with standard of care who had wounds that had failed to heal for periods up to six months healed and in all cases patients experienced significant improvements in healing and pain reduction after treatment with Altrazeal(TM). Assessing the implications of these case studies to attendees, Dr. Niezgoda stated that "we have tested Altrazeal(TM) in the treatment of more than 50 patients. This product is a significant advance in the care and treatment of wounds and will transform the way we do wound care."

Dr. Peter J. Sordi, M.D., FACS, also presented clinical experience from cases of patients under his care. Dr. Sordi reported that one immediate benefit was the reduction of pain in patients treated with Altrazeal(TM). Cases he presented included trauma, venous and arterial ulcers, a midline abdominal wound, and a wound associated with surgical excision of melanoma of the scalp. Patients who had failed alternative therapy experienced excellent healing rates when treated with Altrazeal(TM). Clinical evidence showed that Altrazeal(TM) could be left in place for most patients with no secondary dressing for a period of up to 14 days.

"We are delighted that these distinguished wound care experts are discovering and sharing with their colleagues the unique benefits of treating patients with Altrazeal(TM)," said Kerry P. Gray, President and CEO of ULURU Inc. "These very promising in-clinic results reinforce our belief that Altrazeal(TM) is positioned to revolutionize the way exuding wounds are treated. We are very grateful to Dr. Niezgoda and Dr. Sordi for their pioneering efforts in using Altrazeal(TM), and we look forward to sharing more exciting results from them and the many other wound care specialists across the country who have used the product and others who are eager to put this product to work for their patients."

The session also included a presentation on the composition and properties of Altrazeal(TM) by John V. St. John, Ph.D., Vice President of Material Science at ULURU Inc. Dr. St. John discussed key aspects of the product that provide unique benefits in the treatment of exuding wounds including its high moisture vapor transpiration rate, promotion of an optimal moist wound healing environment, skin-mimetic moisture content, strength and flexibility.

Altrazeal(TM), a transforming powder dressing based on NanoFlex(TM) technology, is a breakthrough new treatment designed specifically for exuding wounds including burns, trauma, skin graft donor sites, surgical wounds and chronic slow-healing wounds such as diabetic foot ulcers, pressure ulcers and venous ulcers. Altrazeal(TM) provides additional patient benefits including reduced pain and enhanced patient comfort, ease of application and removal, and in most cases does not require a secondary dressing.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative NanoFlex(TM) Aggregate technology and transmucosal delivery system. For more information about Altrazeal(TM), please visit http://www.Altrazeal(TM).com. For more information about ULURU Inc., please visit http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the response to the product from patients, the importance of use of the product for acute wounds, the ability to use the product for chronic wounds, the perception of the product as a transformational innovation in the wound care market, the product accelerates healing and decreases pain and dressing changes. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and other reports filed by us with the Securities and Exchange Commission.

Investor contact: Media Contact:

Terry K. Wallberg Stephen Zoegall, Ph.D.

Vice President & CFO Berry & Co. PR

(214) 905-5145 (212) 253-8881

szoegall@berrypr.com


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
10. ULURU Inc. Reports First Quarter 2008 Financial Results
11. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: